Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Asia-Pacific Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991523
Published Content info 180 Pages
Delivery time: 1-2 business days
Price
Back to Top
Asia-Pacific Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 180 Pages
Description

Asia-Pacific pharmacogenetic testing in psychiatry/depression market is projected to register a CAGR of 10.6% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028

Market Segmentation:

Asia-Pacific Pharmacogenetic Testing in Psychiatry/Depression Market, By Type (Whole Genome Sequencing and Array-Based Tests), Genes (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and Others), Drug Type (Prescription Drugs, Over-the-Counter Medications, Recreational Drugs and Vitamins/Nutraceuticals), Sample Type (Saliva and Blood), Application (Drug Development and Clinical Practice), End User (Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, Healthcare Providers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Direct-To-Consumer Services and Mail-Order Pharmacies), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of the Asia-Pacific pharmacogenetic testing in psychiatry/depression market are:

  • Rising population suffering from major depressive disorders
  • Growing demand of personalized medicine

Market Players:

The key market players for Asia-Pacific pharmacogenetic testing in psychiatry/depression market are listed below:

  • BiogeniQ Inc.
  • GenXys
  • Genomind, Inc.
  • Myriad Genetics, Inc.
  • AltheaDx
  • STADA Arzneimittel AG
  • Sonic Healthcare
  • ONEOME
  • Thermo Fisher Scientific Inc.
  • Millennium Health
  • Coriell Life Sciences
  • Healthspek
  • Color
  • GENELEX
  • OmeCare
  • AB-Biotics, S.A.
  • Luminex Corporation
  • Illumina, Inc.
  • PerkinElmer Inc.
  • HudsonAlpha Health Alliance (a division of HudsonAlpha)
  • Dynamic DNA Laboratories
  • cnsdose,
  • myDNA Life Australia Pty Ltd.
  • R-Biopharm AG
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 MARKET APPLICATION COVERAGE GRID
  • 2.11 VENDOR SHARE ANALYSIS
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 REGULATIONS: ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

  • 5.1 UNITED STATES
    • 5.1.1 ROLE OF FDA
    • 5.1.2 ROLE OF CDC AND HCFA
  • 5.2 EUROPEAN UNION
  • 5.3 FRANCE
  • 5.4 AUSTRALIA
  • 5.5 SOUTH KOREA

6 MARKET OVERVIEW

  • 6.1 DRIVERS
    • 6.1.1 RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
    • 6.1.2 INITIATIVES TAKEN BY MANUFACTURERS
    • 6.1.3 GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
    • 6.1.4 INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
    • 6.1.5 GROWING MEDICAL TOURISM
  • 6.2 RESTRAINTS
    • 6.2.1 LACK OF STRONG CLINICAL EVIDENCE
    • 6.2.2 HIGH COST
    • 6.2.3 LACK OF REIMBURSEMENT
  • 6.3 OPPORTUNITIES
    • 6.3.1 TECHNOLOGICAL ADVANCEMENTS
    • 6.3.2 EMERGENCE OF NEW PLAYERS
    • 6.3.3 UNTAPPED MARKET
  • 6.4 CHALLENGES
    • 6.4.1 STRINGENT GOVERNMENT REGULATION
    • 6.4.2 SHORTAGE OF SKILLED PERSONNEL

7 COVID-19 IMPACT ON ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

  • 7.1 IMPACT ON PRICE
  • 7.2 IMPACT ON DEMAND
  • 7.3 IMPACT ON SUPPLY
  • 7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19

7.5 CONCLUSION:

8 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE

  • 8.1 OVERVIEW
  • 8.2 WHOLE GENOME SEQUENCING
  • 8.3 ARRAY-BASED TESTS

9 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES

  • 9.1 OVERVIEW
  • 9.2 CYP2C19
  • 9.3 CYP2C9 AND VKORC1
  • 9.4 CYP2D6
  • 9.5 HLA-B
  • 9.6 HTR2A/C
  • 9.7 HLA-A
  • 9.8 CYP3A4
  • 9.9 SLC6A4
  • 9.10 MTHFR
  • 9.11 COMT
  • 9.12 OTHERS

10 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE

  • 10.1 OVERVIEW
  • 10.2 PRESCRIPTION DRUGS
  • 10.3 OVER-THE-COUNTER MEDICATIONS
  • 10.4 RECREATIONAL DRUGS
  • 10.5 VITAMINS/NUTRACEUTICALS

11 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE

  • 11.1 OVERVIEW
  • 11.2 SALIVA
  • 11.3 BLOOD

12 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION

  • 12.1 OVERVIEW
  • 12.2 DRUG DEVELOPMENT
  • 12.3 CLINICAL PRACTICE

13 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER

  • 13.1 OVERVIEW
  • 13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 13.3 HEALTHCARE PROVIDERS
  • 13.4 RESEARCH CENTERS AND ACADEMIC INSTITUES
  • 13.5 OTHERS

14 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL

  • 14.1 OVERVIEW
  • 14.2 RETAIL PHARMACIES
  • 14.3 HOSPITAL PHARMACIES
  • 14.4 MAIL-ORDER PHARMACIES
  • 14.5 DIRECT-TO-CUSTOMER SERVICES

15 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GEOGRAPHY

  • 15.1 ASIA-PACIFIC
    • 15.1.1 JAPAN
    • 15.1.2 CHINA
    • 15.1.3 SOUTH KOREA
    • 15.1.4 INDIA
    • 15.1.5 AUSTRALIA
    • 15.1.6 SINGAPORE
    • 15.1.7 THAILAND
    • 15.1.8 MALAYSIA
    • 15.1.9 INDONESIA
    • 15.1.10 PHILIPPINES
    • 15.1.11 REST OF ASIA-PACIFIC

16 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE

  • 16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

  • 18.1 MYRIAD GENETICS, INC.
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 COMPANY SHARE ANALYSIS
    • 18.1.4 PRODUCT PORTFOLIO
    • 18.1.5 RECENT DEVELOPMENTS
  • 18.2 THERMO FISHER SCIENTIFIC INC.
    • 18.2.1 COMPANY SNAPSHOT
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 COMPANY SHARE ANALYSIS
    • 18.2.4 PRODUCT PORTFOLIO
    • 18.2.5 RECENT DEVELOPMENT
  • 18.3 STADA ARZNEIMITTEL AG
    • 18.3.1 COMPANY SNAPSHOT
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 COMPANY SHARE ANALYSIS
    • 18.3.4 PRODUCT PORTFOLIO
    • 18.3.5 RECENT DEVELOPMENTS
  • 18.4 SONIC HEALTHCARE
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 REVENUE ANALYSIS
    • 18.4.3 COMPANY SHARE ANALYSIS
    • 18.4.4 PRODUCT PORTFOLIO
    • 18.4.5 RECENT DEVELOPMENT
  • 18.5 ILLUMINA, INC.
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 COMPANY SHARE ANALYSIS
    • 18.5.4 PRODUCT PORTFOLIO
    • 18.5.5 RECENT DEVELOPMENTS
  • 18.6 AB-BIOTICS, S.A.
    • 18.6.1 COMPANY SNAPSHOT
    • 18.6.2 REVENUE ANALYSIS
    • 18.6.3 6.3 PRODUCT PORTFOLIO
    • 18.6.4 RECENT DEVELOPMENTS
  • 18.7 ALTHEADX
    • 18.7.1 COMPANY SNAPSHOT
    • 18.7.2 PRODUCT PORTFOLIO
    • 18.7.3 RECENT DEVELOPMENT
  • 18.8 BIOGENIQ INC.
    • 18.8.1 COMPANY SNAPSHOT
    • 18.8.2 PRODUCT PORTFOLIO
    • 18.8.3 RECENT DEVELOPMENT
  • 18.9 COLOR
    • 18.9.1 COMPANY SNAPSHOT
    • 18.9.2 PRODUCT PORTFOLIO
    • 18.9.3 RECENT DEVELOPMENTS
  • 18.10 CNSDOSE
    • 18.10.1 COMPANY SNAPSHOT
    • 18.10.2 PRODUCT PORTFOLIO
    • 18.10.3 RECENT DEVELOPMENT
  • 18.11 CORIELL LIFE SCIENCES
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 PRODUCT PORTFOLIO
    • 18.11.3 RECENT DEVELOPMENTS
  • 18.12 DYNAMIC DNA LABORATORIES
    • 18.12.1 COMPANY SNAPSHOT
    • 18.12.2 PRODUCT PORTFOLIO
    • 18.12.3 RECENT DEVELOPMENTS
  • 18.13 GENELEX
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 PRODUCT PORTFOLIO
    • 18.13.3 RECENT DEVELOPMENT
  • 18.14 GENOMIND, INC.
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 PRODUCT PORTFOLIO
    • 18.14.3 RECENT DEVELOPMENTS
  • 18.15 GENXYS
    • 18.15.1 COMPANY SNAPSHOT
    • 18.15.2 PRODUCT PORTFOLIO
    • 18.15.3 RECENT DEVELOPMENTS
  • 18.16 HEALTHSPEK
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 PRODUCT PORTFOLIO
    • 18.16.3 RECENT DEVELOPMENT
  • 18.17 HUDSONALPHA HEALTH ALLIANCE (A DIVISION OF HUDSONALPHA)
    • 18.17.1 COMPANY SNAPSHOT
    • 18.17.2 PRODUCT PORTFOLIO
    • 18.17.3 RECENT DEVELOPMENT
  • 18.18 LUMINEX CORPORATION
    • 18.18.1 COMPANY SNAPSHOT
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 PRODUCT PORTFOLIO
    • 18.18.4 RECENT DEVELOPMENTS
  • 18.19 MILLENNIUM HEALTH
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 PRODUCT PORTFOLIO
    • 18.19.3 RECENT DEVELOPMENTS
  • 18.20 MYDNA LIFE AUSTRALIA PTY LTD.
    • 18.20.1 COMPANY SNAPSHOT
    • 18.20.2 PRODUCT PORTFOLIO
    • 18.20.3 RECENT DEVELOPMENT
  • 18.21 ONEOME
    • 18.21.1 COMPANY SNAPSHOT
    • 18.21.2 PRODUCT PORTFOLIO
    • 18.21.3 RECENT DEVELOPMENTS
  • 18.22 OMECARE
    • 18.22.1 COMPANY SNAPSHOT
    • 18.22.2 PRODUCT PORTFOLIO
    • 18.22.3 RECENT DEVELOPMENT
  • 18.23 PERKINELMER INC.
    • 18.23.1 COMPANY SNAPSHOT
    • 18.23.2 REVENUE ANALYSIS
    • 18.23.3 PRODUCT PORTFOLIO
    • 18.23.4 RECENT DEVELOPMENTS
  • 18.24 R-BIOPHARM AG
    • 18.24.1 COMPANY SNAPSHOT
    • 18.24.2 PRODUCT PORTFOLIO
    • 18.24.3 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD MILLION)
  • TABLE 2 ASIA-PACIFIC WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 3 ASIA-PACIFIC ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 4 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD MILLION)
  • TABLE 5 ASIA-PACIFIC CYP2C19 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 6 ASIA-PACIFIC CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 7 ASIA-PACIFIC CYP2D6 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 8 ASIA-PACIFIC HLA-B IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 9 ASIA-PACIFIC HTR2A/C IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 10 ASIA-PACIFIC HLA-A IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 11 ASIA-PACIFIC CYP3A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 12 ASIA-PACIFIC SLC6A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 13 ASIA-PACIFIC MTHFR IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 14 ASIA-PACIFIC COMT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 15 ASIA-PACIFIC OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 16 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD MILLION)
  • TABLE 17 ASIA-PACIFIC PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 18 ASIA-PACIFIC OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 19 ASIA-PACIFIC RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 20 ASIA-PACIFIC VITAMINS/NUTRACEUTICALS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 21 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD MILLION)
  • TABLE 22 ASIA-PACIFIC SALIVA IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 23 ASIA-PACIFIC BLOOD IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 24 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD MILLION)
  • TABLE 25 ASIA-PACIFIC DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 26 ASIA-PACIFIC CLINICAL PRACTICE IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 27 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD MILLION)
  • TABLE 28 ASIA-PACIFIC PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 29 ASIA-PACIFIC HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 30 ASIA-PACIFIC RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 31 ASIA-PACIFIC OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 32 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD MILLION)
  • TABLE 33 ASIA-PACIFIC RETAIL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 34 ASIA-PACIFIC HOSPITAL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 35 ASIA-PACIFIC MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION))
  • TABLE 36 ASIA-PACIFIC DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 37 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
  • TABLE 38 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 39 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 40 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 41 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 42 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 43 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 44 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 45 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 46 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 47 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 48 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 49 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 50 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 51 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 52 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 53 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 54 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 55 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 56 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 57 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 58 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 59 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 60 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 61 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 62 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 63 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 64 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 65 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 66 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 67 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 68 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 69 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 70 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 71 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 72 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 73 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 74 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 75 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 76 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 77 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 78 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 79 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 80 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 81 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 82 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 83 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 84 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 85 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 86 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 87 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 88 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 89 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 90 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 91 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 92 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 93 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 94 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 95 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 96 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 97 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 98 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 99 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 100 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 101 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 102 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 103 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 104 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 105 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 106 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 107 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 108 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 109 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)
  • TABLE 110 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 111 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • TABLE 112 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 113 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 114 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 115 REST OF ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 ASIA-PACIFIC PHARMACOGENTIC TESTIG IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION
  • FIGURE 2 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DATA TRIANGULATION
  • FIGURE 3 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DROC ANALYSIS
  • FIGURE 4 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: MARKET APPLICATION COVERAGE GRID
  • FIGURE 9 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 10 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION
  • FIGURE 11 INITIATIVES TAKEN BY MANUFACTURERS IS EXPECTED TO DRIVE THE ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 12 WHOLE GENOME SEQUENCING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET IN 2021 & 2028
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
  • FIGURE 14 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028
  • FIGURE 15 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028 (USD MILLION)
  • FIGURE 16 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)
  • FIGURE 17 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE
  • FIGURE 18 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028
  • FIGURE 19 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028 (USD MILLION)
  • FIGURE 20 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR (2021-2028)
  • FIGURE 21 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE
  • FIGURE 22 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028
  • FIGURE 23 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028 (USD MILLION)
  • FIGURE 24 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
  • FIGURE 25 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE
  • FIGURE 26 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028
  • FIGURE 27 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • FIGURE 28 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
  • FIGURE 29 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE
  • FIGURE 30 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028
  • FIGURE 31 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
  • FIGURE 32 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR (2021-2028)
  • FIGURE 33 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE
  • FIGURE 34 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028
  • FIGURE 35 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028 (USD MILLION)
  • FIGURE 36 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2021-2028)
  • FIGURE 37 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 38 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028
  • FIGURE 39 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • FIGURE 40 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
  • FIGURE 41 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 42 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
  • FIGURE 43 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
  • FIGURE 44 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 45 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 46 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE (2021-2028)
  • FIGURE 47 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2020 (%)
Back to Top